Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 19;24(14):11649.
doi: 10.3390/ijms241411649.

Bradykinin Metabolism and Drug-Induced Angioedema

Affiliations
Review

Bradykinin Metabolism and Drug-Induced Angioedema

Sylwia Smolinska et al. Int J Mol Sci. .

Abstract

Bradykinin (BK) metabolism and its receptors play a central role in drug-induced angioedema (AE) without urticaria through increased vascular permeability. Many cardiovascular and diabetic drugs may cause BK-mediated AE. Angiotensin-converting enzyme inhibitors (ACEIs) and neprilysin inhibitors impair BK catabolism. Dipeptidyl peptidase-IV (DPP-IV) inhibitors reduce the breakdown of BK and substance P (SP). Moreover, angiotensin receptor blockers, thrombolytic agents, and statins may also induce BK-mediated AE. Understanding pathophysiological mechanisms is crucial for preventing and treating drug-induced AE.

Keywords: bradykinin metabolism; drug-induced angioedema.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structure of BK and sites of cleavage by significant enzymes related to drug-induced AE. Note: The amino acid sequence of BK is Arginine (Arg)–Proline (Pro)–Proline (Pro)–Glycine (Gly)–Phenylalanine (Phe)–Serine (Ser)–Proline (Pro)–Phenylalanine (Phe)–Arginine (Arg). Figure adapted from [23] for a simplified presentation of the sites of cleavage of BK by different important enzymes, marked with red arrows for ACE (angiotensin-converting enzyme), APP (aminopeptidase P), NEP (neutral endopeptidase), CPN (carboxypeptidase N), and DPPIV (dipeptidyl peptidase IV).
Figure 2
Figure 2
Overall presentation of different causes of angioedema classified by pathophysiology mechanisms, focusing on bradikinergic or BK-mediated angioedema (BK-AE) and drug-induced forms [3,47,109]. * Hereditary angioedema (HAE) with C1-INH deficiency with low antigenic and functional C1-INH levels (HAE-1, 85% of cases), HAE due to C1-INH dysfunction (HAE-2, 10% of cases) characterized by normal or elevated antigenic but low functional C1-INH levels, and HAE with normal C1-INH (HAE-nC1-INH, 5% of cases) due to various gene mutations. ** Acquired forms of BK-AE include drug-induced AE, such as AE induced by angiotensin-converting enzyme inhibitors (ACEIs), AE due to acquired C1-INH deficiency (AAE-C1-INH), and acquired idiopathic non-histaminergic AE. *** Mast cell-mediated angioedema (MC-AE) includes allergic IgE-mediated reactions (such as AE with anaphylaxis), nonallergic non-IgE-mediated reactions (such as AE due to non-steroidal anti-inflammatory drugs or infections), AE in chronic inducible urticaria or chronic spontaneous urticaria (sometimes referred to as idiopathic histaminergic acquired AE). The diversity of mediators involved in MC-AE is reflected also by the fact that patients with chronic spontaneous urticaria may respond to treatment with omalizumab but not to H1 antihistamines.
Figure 3
Figure 3
Metabolism of bradykinin (BK) and angioedema induced by cardiovascular and antidiabetic drugs: angiotesin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (sartans), neprilysin inhibitors, direct renin inhibitor (aliskiren), gliptins (DPP-IV inhibitors), and recombinant tissue plasminogen activators (rt-PAs), figure created and adapted after [23,57,87,111].

Similar articles

Cited by

References

    1. Bernstein J.A., Moellman J. Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. Int. J. Emerg. Med. 2012;5:39. doi: 10.1186/1865-1380-5-39. - DOI - PMC - PubMed
    1. Mudd P.A., Hooker E.A., Stolz U., Hart K.W., Bernstein J.A., Moellman J.J. Emergency department evaluation of patients with angiotensin converting enzyme inhibitor associated angioedema. Am. J. Emerg. Med. 2020;38:2596–2601. doi: 10.1016/j.ajem.2019.12.058. - DOI - PubMed
    1. Ferrer M., Rodriguez-Garijo N., Sabate-Bresco M. Medical algorithm: Diagnosis and management of histaminergic angioedema. Allergy. 2023;78:599–602. doi: 10.1111/all.15618. - DOI - PubMed
    1. Bernstein J.A., Cremonesi P., Hoffmann T.K., Hollingsworth J. Angioedema in the emergency department: A practical guide to differential diagnosis and management. Int. J. Emerg. Med. 2017;10:15. doi: 10.1186/s12245-017-0141-z. - DOI - PMC - PubMed
    1. Long B.J., Koyfman A., Gottlieb M. Evaluation and Management of Angioedema in the Emergency Department. West. J. Emerg. Med. 2019;20:587–600. doi: 10.5811/westjem.2019.5.42650. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources